Saturday, January 18, 2020 3:55:28 PM
This is what another company is doing:
New Israeli Cancer Treatment Has a 100% Tumor Shrinkage Rate
The treatment called ALPHA DaRT delivered total tumor destruction in over 78% of cases.
By Loukia Papadopoulos - January 01, 2020
Israeli firm Alpha Tau Medical has developed a new cancer treatment that attacks tumors while sparing healthy tissue. The treatment is called Alpha DaRT (Diffusing Alpha-emitters Radiation Treatment), according to The Jerusalem Post.
A tolerable treatment
Alpha DaRT uses, for the first time, alpha radiation for solid tumor treatment. But it does so in a way that the body can tolerate it.
Most cancer treatments out there are simply not tolerable. Our bodies were not made to be exposed to them.
Alpha particles have a high capacity to destroy cancer cells without causing side effects on healthy cells. However, they have extremely short path length in tissue, meaning that up to now they could not get across the entire volume of a tumor.
Recent TLTFF News
- Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update • Newsfile • 05/04/2026 09:22:00 PM
- Theralase(R) Closes $CAN 2.66 Million Financing • Newsfile • 04/10/2026 11:00:00 AM
- Theralase(R) Closes $1.1 M Non-Brokered Private Placement • Newsfile • 03/10/2026 11:00:00 AM
- Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer • Newsfile • 03/09/2026 11:00:00 AM
- Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress • Newsfile • 02/20/2026 12:00:00 PM
- Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress • Newsfile • 02/17/2026 12:00:00 PM
- Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting • Newsfile • 02/10/2026 12:00:00 PM
- Theralase(R) Provides Update on Bladder Cancer Clinical Study • Newsfile • 02/04/2026 12:00:00 PM
- Theralase and Ferring ink deal for new bladder cancer study • IH Market News • 01/14/2026 11:05:00 AM
- New Bladder Cancer Collaboration Sparks Sharp Rally in This Micro Cap Stock • AllPennyStocks.com • 01/12/2026 03:23:00 PM
- Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer • Newsfile • 01/12/2026 12:00:00 PM
- Theralase(R) Closes $1.3 M Non-Brokered Private Placement • Newsfile • 12/23/2025 09:40:00 PM
- Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing • Newsfile • 12/12/2025 10:00:00 PM
- Theralase(R) Investor Conference Call Reminder • Newsfile • 11/17/2025 12:00:00 PM
- Theralase(R) Releases 3Q2025 Financial Statements • Newsfile • 11/10/2025 12:00:00 PM
- Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus • Newsfile • 09/24/2025 11:00:00 AM
